Sandostatin lar and Breakthrough pain - a phase IV clinical study of FDA data

Summary:

Breakthrough pain is reported as a side effect among people who take Sandostatin lar (octreotide acetate), especially for people who are female, 60+ old, also take Sandostatin, and have Abdominal pain.

The phase IV clinical study analyzes which people have Breakthrough pain when taking Sandostatin lar. It is created by eHealthMe based on reports of 38,376 people who have side effects when taking Sandostatin lar from the FDA, and is updated regularly.

What is Sandostatin lar?

Sandostatin lar has active ingredients of octreotide acetate. It is often used in acromegaly. eHealthMe is studying from 38,437 Sandostatin lar users. Check the latest studies of Sandostatin lar.

What is Breakthrough pain?

Breakthrough pain is found to be associated with 271 drugs and 417 conditions by eHealthMe. Check the latest studies of Breakthrough pain.

On Jul, 17, 2026

38,376 people reported to have side effects when taking Sandostatin lar.
Among them, 35 people (0.09%) have Breakthrough pain.

Could Sandostatin lar cause Breakthrough pain?

Among these 35 people:

What is the gender of people who have Breakthrough pain when taking Sandostatin lar? *

female: 74.29 %
male: 25.71 %

What is the age of people who have Breakthrough pain when taking Sandostatin lar? *

What are other drugs people take besides Sandostatin lar? *

What are other side effects people have besides Breakthrough pain? *

High Blood Pressure: 29 people, 82.86%
Injection Site Pain: 26 people, 74.29%
Abdominal Pain: 25 people, 71.43%
Diarrhea: 23 people, 65.71%
Nausea And Vomiting: 19 people, 54.29%
Urination - Painful: 18 people, 51.43%
Chest Pain: 17 people, 48.57%
Peripheral Swelling: 17 people, 48.57%
Hyperhidrosis (abnormally increased sweating): 17 people, 48.57%
Dyspnea (difficult or laboured breathing): 17 people, 48.57%

What are the existing conditions these people have? *

Diarrhea: 16 people, 45.71%
Abdominal Pain: 16 people, 45.71%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 15 people, 42.86%
Hyperhidrosis (abnormally increased sweating): 15 people, 42.86%
Pain: 12 people, 34.29%
Gastrointestinal Carcinoma (cancer of stomach or intestine): 12 people, 34.29%
Brain Neoplasm (tumour of brain): 12 people, 34.29%
Metastatic Carcinoid Tumor: 9 people, 25.71%
Carcinoid Tumor: 4 people, 11.43%
Pancreatic Neuroendocrine Tumor Metastatic: 1 person, 2.86%

* Approximation only. Some reports may have incomplete information.

Do you take Sandostatin lar and have Breakthrough pain?

- Check whether Breakthrough pain is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Sandostatin lar:

Sandostatin lar (38,437 reports)

Browse all side effects of Sandostatin lar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Breakthrough pain:

Breakthrough pain (271 drugs)

Browse all the conditions that are associated with Breakthrough pain:

Breakthrough pain (417 conditions)

Related publications that referenced our studies

Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .
Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on octreotide acetate (the active ingredients of Sandostatin lar) and Sandostatin lar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.